does masshealth cover semaglutide Our Clinical Supervisor, Joseph Zucchi, PA-C, has a new op-ed published on Itemlive regarding the fight to protect access to obesity treatment in Massachusetts. Patients who are finally improving their health may GLP-1 medications for obesity treatment

This includes careful consideration of medication selection, route of administration (oral, injection, infusion), frequency with which someone monitors blood glucose and adjusts dosage, benefits and risks that the patient experiences and/or tolerates, and lifestyle changes the patient is willing or able to make

Abnormal blood vessels in the esophagus, stomach, or duodenum Conditions such as esophageal varices or gastric varices, which are enlarged and fragile blood vessels, can cause bleeding and result in black, tarry stools

However, Novo Nordisk still has patent exclusivity for Ozempic, at least until 2033

Real results from lifestyle change alone, with a host of other health benefits alongside them

Complete weight regain occurred in 23% of semaglutide, 21% of tirzepatide, and 27% of liraglutide users at 24 months

Expected Outcome Patients can expect gradual and sustained weight loss over the course of the treatment